

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

REGENERON PHARMACEUTICALS, INC.,
Appellant

v.

**MYLAN PHARMACEUTICALS INC., CELLTRION,
INC., SAMSUNG BIOEPIS CO., LTD.,**
Appellees

2024-1564, 2024-1567

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2022-01225, IPR2022-01226, IPR2023-00532, IPR2023-00533, and IPR2023-00566.

ON MOTION

O R D E R

Upon consideration of Regeneron Pharmaceuticals, Inc.'s unopposed motion to voluntarily dismiss the above-captioned appeals pursuant to Federal Rule of Appellate Procedure 42,

2

REGENERON PHARMACEUTICALS, INC. v. MYLAN
PHARMACEUTICALS INC.

IT IS ORDERED THAT:

- (1) The motion is granted, and the appeals are dismissed.
- (2) Each party shall bear its own costs for each appeal.

FOR THE COURT



Jarrett B. Perlow
Clerk of Court

August 20, 2024
Date

ISSUED AS A MANDATE: August 20, 2024